Thirty-three hemodialysis patients were randomized into two treatment groups , valsartan 80 to 320 mg/day ( n = 18 ) or non-renin-angiotensin-aldosterone-system blocking antihypertensive agents ( control , n = 15 ) , treated for 12 weeks .